OSU-53 is an orally active AMPK activator (EC50: 0.3 μM) and a direct mTOR inhibitor; it induces autophagy and increases the conversion ratio of LC3I to LC3II; it also suppresses fatty acid biosynthesis, enhances PGC1α and NRF-1 expression, thereby modulating energy homeostasis and shifting metabolism toward oxidation; it exhibits antitumor activity in various cancer models, including breast cancer and thyroid cancer.